Johnson & Johnson deal still on track after FTC (Federal Trade Commission) request:
This article was originally published in Clinica
Johnson & Johnson still expects to close its $25.4bn acquisition of Guidant during the third quarter of 2005, it said after the US Federal Trade Commission requested additional information from the companies. Close scrutiny by the FTC was expected, because J&J's Cordis unit and Guidant both make stents. Cordis sells the Cypher drug-eluting stent, and Guidant is developing a rival product. The nature of the information requested was not disclosed.